Home/Mereo BioPharma/Dr. Denise Scots-Knight
DD

Dr. Denise Scots-Knight

Chief Executive Officer

Mereo BioPharma

Mereo BioPharma Pipeline

DrugIndicationPhase
Setrusumab (UX-143)Osteogenesis ImperfectaPhase 3
Alvelestat (MPH966)Alpha-1 Antitrypsin Deficiency-associated Lung DiseasePhase 2
Etigilimab (MPH313)Advanced Solid TumorsPhase 1b
Leflutrozole (MPH-220)Hypogonadotropic HypogonadismPhase 2b